Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Advanced Drug Delivery Reviews

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.addr.2016.04.013PMID 27108702
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

  2016cited by this paper
• Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs

  2016cited by this paper
• Bio-inspired pulmonary surfactant-modified nanogels: A promising siRNA delivery system.

  2015cited by this paper
• siRNA Versus miRNA as Therapeutics for Gene Silencing

  2015cited by this paper
• Unique role for ATG5 in PMN-mediated immunopathology during M. tuberculosis infection

  2015cited by this paper
• Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system.

  2015cited by this paper
• Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier.

  2015cited by this paper
• Neutrophil-Derived MMP-8 Drives AMPK-Dependent Matrix Destruction in Human Pulmonary Tuberculosis

  2015cited by this paper
• Devices for Dry Powder Drug Delivery to the Lung

  2015cited by this paper
• New tricks for old dogs: countering antibiotic resistance in tuberculosis with host‐directed therapeutics

  2015cited by this paper
• Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study

  2015cited by this paper
• MicroRNA-125a Inhibits Autophagy Activation and Antimicrobial Responses during Mycobacterial Infection

  2015cited by this paper
• Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages.

  2015cited by this paper
• Bedaquiline and delamanid in tuberculosis

  2015cited by this paper
• Barrier or carrier? Pulmonary surfactant and drug delivery.

  2015cited by this paper
• Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation.

  2015cited by this paper
• Towards host-directed therapies for tuberculosis

  2015cited by this paper
• Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.

  2015cited by this paper
• Exploring the potential of adjunct therapy in tuberculosis.

  2015cited by this paper
• Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation.

  2015cited by this paper
• New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

  2015cited by this paper
• Tuberculosis: Autophagy is not the answer

  2015cited by this paper
• Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.

  2015cited by this paper
• Pulmonary drug delivery systems for tuberculosis treatment.

  2015cited by this paper
• Nano-carrier systems: Strategies to overcome the mucus gel barrier.

  2015cited by this paper
• Cytokine and lipid mediator networks in tuberculosis

  2015cited by this paper
• Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexes.

  2015cited by this paper
• Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.

  2014cited by this paper
• Development of Pre-Clinical Models for Evaluating the Therapeutic Potential of Candidate siRNA Targeting STAT6

  2014cited by this paper
• Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma

  2014cited by this paper
• siRNA delivery to the lung: what's new?

  2014cited by this paper
• Major degradable polycations as carriers for DNA and siRNA.

  2014cited by this paper
• Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis

  2014cited by this paper
• Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

  2014cited by this paper
• Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury.

  2014cited by this paper
• Recent advances in nanoparticle-mediated siRNA delivery.

  2014cited by this paper
• Extensively drug-resistant tuberculosis: epidemiology and management

  2014cited by this paper
• First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

  2014cited by this paper
• RNA interference-based therapeutics: molecular platforms for infectious diseases.

  2014cited by this paper
• Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

  2014cited by this paper
• Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.

  2014cited by this paper
• Technological and practical challenges of dry powder inhalers and formulations.

  2014cited by this paper
• Multifunctional polymeric micelles for delivery of drugs and siRNA

  2014cited by this paper
• Development of microRNA therapeutics is coming of age

  2014cited by this paper
• Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.

  2014cited by this paper
• Non-viral vectors for gene-based therapy

  2014cited by this paper
• Small Interfering RNAs Targeted to Interleukin-4 and Respiratory Syncytial Virus Reduce Airway Inflammation in a Mouse Model of Virus-Induced Asthma Exacerbation

  2014cited by this paper
• Macrophage immunoregulatory pathways in tuberculosis.

  2014cited by this paper
• Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.

  2013cited by this paper
• Enhanced Intrapulmonary Delivery of Anticancer siRNA for Lung Cancer Therapy Using Cationic Ethylphosphocholine-based Nanolipoplexes

  2013cited by this paper
• RNAi Therapeutic Platforms for Lung Diseases

  2013cited by this paper
• In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models.

  2013cited by this paper
• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

  2013cited by this paper
• Platforms for antibiotic discovery

  2013cited by this paper
• MicroRNA-155 Promotes Autophagy to Eliminate Intracellular Mycobacteria by Targeting Rheb

  2013cited by this paper
• Targeting cell motility in pulmonary arterial hypertension

  2013cited by this paper
• Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.

  2013cited by this paper
• Inhalation drug delivery : techniques and products

  2013cited by this paper
• Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment.

  2013cited by this paper
• Host-Directed Therapeutics for Tuberculosis: Can We Harness the Host?

  2013cited by this paper
• Receptor-Interacting Protein 2 Gene Silencing Attenuates Allergic Airway Inflammation

  2013cited by this paper
• Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique.

  2013cited by this paper
• Modeling the proton sponge hypothesis: examining proton sponge effectiveness for enhancing intracellular gene delivery through multiscale modeling

  2013cited by this paper
• Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis.

  2013cited by this paper
• Use of single-site-functionalized PEG dendrons to prepare gene vectors that penetrate human mucus barriers.

  2013cited by this paper
• Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

  2013cited by this paper
• microRNA regulation of inflammatory responses.

  2012cited by this paper
• Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

  2012cited by this paper
• Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.

  2012cited by this paper
• Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages

  2012cited by this paper
• Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.

  2012cited by this paper
• Endosomal Escape Pathways for Non-Viral Nucleic Acid Delivery Systems

  2012cited by this paper
• Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis.

  2012cited by this paper
• Pulmonary gene delivery using polymeric nonviral vectors.

  2012cited by this paper
• The Tuberculous Granuloma: An Unsuccessful Host Defence Mechanism Providing a Safety Shelter for the Bacteria?

  2012cited by this paper
• Challenges with Developing In Vitro Dissolution Tests for Orally Inhaled Products (OIPs)

  2012cited by this paper
• Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products

  2012cited by this paper
• Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways.

  2012cited by this paper
• Controlled pulmonary drug and gene delivery using polymeric nano-carriers.

  2012cited by this paper
• RNA Interference Technologies and Therapeutics

  2012cited by this paper
• Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection.

  2011cited by this paper
• RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.

  2011cited by this paper
• Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.

  2011cited by this paper
• Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

  2011cited by this paper
• RNA interference in the clinic: challenges and future directions

  2011cited by this paper
• Pulmonary delivery of therapeutic siRNA

  2011cited by this paper
• Role of autophagy in the host response to microbial infection and potential for therapy.

  2011cited by this paper
• Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice

  2011cited by this paper
• Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice.

  2011cited by this paper
• Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders

  2011cited by this paper
• The role of IL-10 in immune regulation during M. tuberculosis infection

  2011cited by this paper
• Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.

  2011cited by this paper
• Bfl-1/A1 acts as a negative regulator of autophagy in mycobacteria infected macrophages.

  2011cited by this paper
• Inhaled drug therapy for treatment of tuberculosis.

  2011cited by this paper
• Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs

  2011cited by this paper
• Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.

  2011cited by this paper
• The promise of microRNA replacement therapy.

  2010cited by this paper
• Identification of Host-Dependent Survival Factors for Intracellular Mycobacterium tuberculosis through an siRNA Screen

  2010cited by this paper
• Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.

  2010cited by this paper
• Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis

  2010cited by this paper

• Inhaled non-viral delivery systems for RNA therapeutics

  2025cites this paper
• Has-miR-30c-1-3p inhibits macrophage autophagy and promotes Mycobacterium tuberculosis survival by targeting ATG4B and ATG9B

  2025cites this paper
• Influenza Virus Genomic Mutations, Host Barrier and Cross-species Transmission

  2024cites this paper
• Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases

  2022cites this paper
• Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment

  2022cites this paper
• Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application

  2022cites this paper
• Understanding microRNAs in the Context of Infection to Find New Treatments against Human Bacterial Pathogens

  2022cites this paper
• Modulatory effect of Tim-3/Galectin-9 axis on T-cell-mediated immunity in pulmonary tuberculosis

  2020cites this paper
• Aerosols in pharmaceutical product development

  2020cites this paper
• Modulatory effect of Tim-3/Galectin-9 axis on T-cell-mediated immunity in pulmonary tuberculosis

  2020cites this paper
• Host-directed targeting of lincRNA-MIR99AHG suppresses intracellular growth of Mycobacterium tuberculosis

  2020cites this paper
• Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: Design, development and in vitro evaluation

  2020cites this paper
• Targeting tuberculosis infection in macrophages using chitosan oligosaccharide nanoplexes

  2019cites this paper
• The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

  2019cites this paper
• Short hairpin RNAs targeting M and N genes reduce replication of porcine deltacoronavirus in ST cells

  2019cites this paper
• Poly(glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA

  2018cites this paper
• Drug Delivery Strategies For The Treatment Of Advanced Lung Cancer And Various Lung Metastases

  2018cites this paper
• Title Spray freeze drying of small nucleic acids as inhaled powder forpulmonary delivery

  2018cites this paper
• MicroRNA-27a controls the intracellular survival of Mycobacterium tuberculosis by regulating calcium-associated autophagy

  2018cites this paper
• TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.

  2017cites this paper
• MicroRNA in innate immunity and autophagy during mycobacterial infection

  2017cites this paper
• Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery

  2017cites this paper
• Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers.

  2017cites this paper
• Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside

  2016cites this paper
• Hastalıkların tanı ve tedavi stratejilerinde miRNA ve diğer non-protein-coding RNA’lar

  2016cites this paper